UTI vaccine
vaccine to prevent urinary tract infections
A UTI vaccine is a vaccine used for prevention of recurrent urinary tract infections (UTIs). A number of UTI vaccines have been developed and/or marketed. These include Uromune (MV-140; sublingual spray), UroVaxom (OM-89, OM-8980; oral tablet), Solco-Urovac (Strovac; vaginal suppository or intramuscular injection), ExPEC4V (V10, JNJ-63871860; intramuscular injection), and SEQ-400 (route unspecified).
Background
Recurrent UTIs are common in women, causing significant physical and emotional distress. While antibiotics are widely used to treat them, the recurrence of UTIs poses a significant challenge. Long-term antibiotic use not only poses health risks but also contributes to the growing problem of antibiotic resistance, making effective treatment more challenging.
Uromune (MV-140)
Uromune (developmental code name MV-140) is a vaccine developed to treat recurrent UTIs that is made from heat-inactivated bacteria mixed with in glycerol, sodium chloride, artificial pineapple flavoring, and water. It contains specific strains of four types of bacteria: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris.
This vaccine is taken by spraying it under the tongue twice a day for three months. It is currently being tested in clinical trials.
Begin with the source’s own compact description: “UTI vaccine” is vaccine to prevent urinary tract infections. The dossier treats that line as a proposition to test through vaccine, prevent and urinary, not as a finished interpretation.
Why this record matters
The phrase “vaccine to prevent urinary tract infections” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated May 22, 2026. The linked authority identifier is Q124727477. None of the 0 selected statements returned an explicit reference.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “UTI vaccine”, its source revision and the description used here.
- Expand the search: follow UTI vaccine primary sources, UTI vaccine archive and vaccine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “UTI vaccine”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “UTI vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.